Topical Agent for Treatment of Red Skin

This study is ongoing, but not recruiting participants.

Sponsored by:	Mayo Clinic
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00279890

Purpose

SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety

Condition	Intervention	Phase
Rosacea Bilaterally Symmetric Red Skin on Cheeks	Drug: Topical SR-01	Phase I

MedlinePlus related topics: Rosacea

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Proof of Concept Trial:SR-01 for the Treatment of Rosacea

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Reduction of redness

Secondary Outcome Measures:

Safety and tolerability
Cosmetic acceptability

Estimated Enrollment:	20
Study Start Date:	July 2005

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Bilaterally symmetric red skin on cheeks Caucasian Age 18-60 years

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279890

Locations

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 55259

Sponsors and Collaborators

Mayo Clinic

Investigators

Principal Investigator:

Mark V. Dahl, M.D.

Mayo Clinic

More Information

Study ID Numbers:	44-05, MCS 385
Study First Received:	January 18, 2006
Last Updated:	July 1, 2006
ClinicalTrials.gov Identifier:	NCT00279890
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Rosacea
Erythema
Skin Diseases

ClinicalTrials.gov processed this record on January 16, 2009